Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Retained Earnings (2016 - 2025)

Palisade Bio has reported Retained Earnings over the past 16 years, most recently at -$152.7 million for Q4 2025.

  • Quarterly Retained Earnings fell 12.34% to -$152.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$152.7 million through Dec 2025, down 12.34% year-over-year, with the annual reading at -$152.7 million for FY2025, 12.34% down from the prior year.
  • Retained Earnings was -$152.7 million for Q4 2025 at Palisade Bio, down from -$143.8 million in the prior quarter.
  • Over five years, Retained Earnings peaked at -$2776.0 in Q1 2021 and troughed at -$152.7 million in Q4 2025.
  • The 5-year median for Retained Earnings is -$116.7 million (2023), against an average of -$113.7 million.
  • Year-over-year, Retained Earnings skyrocketed 61.16% in 2021 and then tumbled 3560670.89% in 2022.
  • A 5-year view of Retained Earnings shows it stood at -$94.6 million in 2021, then fell by 15.37% to -$109.2 million in 2022, then decreased by 11.28% to -$121.5 million in 2023, then fell by 11.88% to -$135.9 million in 2024, then fell by 12.34% to -$152.7 million in 2025.
  • Per Business Quant, the three most recent readings for PALI's Retained Earnings are -$152.7 million (Q4 2025), -$143.8 million (Q3 2025), and -$141.0 million (Q2 2025).